Disease Activity

Response to: ‘Novel NLRP12 variant presenting with familial cold autoimmunity syndrome phenotype’ by Gupta et al
Charlotte Eijkelboom, Nienke M Ter Haar, Joost Frenkel, Marco Gattorno

Annals of the Rheumatic Diseases Jul 2021, 80 (7) e118; DOI: 10.1136/annrheumdis-2019-216184
Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients
Ricardo J O Ferreira, Paco M J Welsing, Johannes W G Jacobs, Laure Gossec, Mwidimi Ndosi, Pedro M Machado, Désirée van der Heijde, Jose A P Da Silva

Annals of the Rheumatic Diseases Mar 2021, 80 (3) 293-303; DOI: 10.1136/annrheumdis-2020-217171
Response to: ‘On using machine learning algorithms to define clinically meaningful patient subgroups’ by Knevel and Huizinga
Alain Meyer, Lionel Spielmann, François Séverac

Annals of the Rheumatic Diseases Dec 2020, 79 (12) e155; DOI: 10.1136/annrheumdis-2019-215989
Performance of the systemic lupus erythematosus disease activity score (SLE-DAS) in a Latin American population.
Melissa G Rodríguez-González, Grissell A Valero-Gaona, Tania Vargas-Aguirre, Luis M Amezcua Guerra

Annals of the Rheumatic Diseases Dec 2020, 79 (12) e158; DOI: 10.1136/annrheumdis-2019-216028
Response to: “How to communicate in science” by Klareskog et al
René Toes, David S Pisetsky

Annals of the Rheumatic Diseases Dec 2020, 79 (12) e165; DOI: 10.1136/annrheumdis-2019-216045
DAPSA versus cDAPSA: Do we need to use CRP?
Rafaela Silva Guimarães Gonçalves, Lays Miranda de Almeida Martins, Henrique de Ataide Mariz, Andrea Tavares Dantas, Angela Luzia Branco Pinto Duarte

Annals of the Rheumatic Diseases Nov 2020, 79 (11) e142; DOI: 10.1136/annrheumdis-2019-215960
Response to: ‘Achieving lupus low disease activity and remission states under belimumab in refractory systemic lupuserythematosus: time and organ involvement matter’ by Sbeih et al
Mandana Nikpour, Molla Huq, Shereen Oon

Annals of the Rheumatic Diseases Nov 2020, 79 (11) e149; DOI: 10.1136/annrheumdis-2019-215922
Response to: ‘Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations’ by Orsolini et al
Antonis Fanouriakis, George Bertsias, Dimitrios T Boumpas

Annals of the Rheumatic Diseases Nov 2020, 79 (11) e151; DOI: 10.1136/annrheumdis-2019-215944
Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence
Bon San Koo, Ji Seon Oh, Seo Young Park, Ji Hui Shin, Ga Young Ahn, Seunghun Lee, Kyung Bin Joo, Tae-Hwan Kim

Annals of the Rheumatic Diseases Oct 2020, 79 (10) 1327-1332; DOI: 10.1136/annrheumdis-2019-216741
Response to: ‘Impact of Janus kinase inhibitors on the risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials’ by Lee and Song
Wenhui Xie, Shiyu Xiao, Zhuoli Zhang

Annals of the Rheumatic Diseases Oct 2020, 79 (10) e123; DOI: 10.1136/annrheumdis-2019-215841

Main menu

Disease Activity

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Disease Activity

Pages